Journal home
Advance online publication
Current issue
Archive
Press releases
Supplements
Focuses
Guide to authors
Online submissionOnline submission
For referees
Free online issue
Contact the journal
Subscribe
Advertising
work@npg
Reprints and permissions
About this site
For librarians
 
NPG Resources
Nature
Nature Reviews
Nature Immunology
Nature Cell Biology
Nature Genetics
news@nature.com
Nature Conferences
Dissect Medicine
NPG Subject areas
Biotechnology
Cancer
Chemistry
Clinical Medicine
Dentistry
Development
Drug Discovery
Earth Sciences
Evolution & Ecology
Genetics
Immunology
Materials Science
Medical Research
Microbiology
Molecular Cell Biology
Neuroscience
Pharmacology
Physics
Browse all publications
Letter
Nature Medicine  11, 429 - 433 (2005)
Published online: 13 March 2005; | doi:10.1038/nm1205

Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model

G Scott Ralph1, Pippa A Radcliffe1, Denise M Day1, Janine M Carthy1, Marie A Leroux1, Debbie C P Lee1, Liang-Fong Wong1, Lynsey G Bilsland2, Linda Greensmith2, Susan M Kingsman1, Kyriacos A Mitrophanous1, Nicholas D Mazarakis1 & Mimoun Azzouz1

1  Oxford Biomedica (UK) Ltd, Medawar Centre, The Oxford Science Park, Oxford, OX4 4GA, UK.

2  Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, Queen Square, London, WC1N 3BG, UK.

Correspondence should be addressed to G Scott Ralph s.ralph@oxfordbiomedica.co.uk or Mimoun Azzouz m.azzouz@oxfordbiomedica.co.uk
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease resulting in the selective death of motor neurons in the brain and spinal cord1. Some familial cases of ALS are caused by dominant mutations in the gene encoding superoxide dismutase (SOD1)2, 3, 4. The emergence of interfering RNA (RNAi) for specific gene silencing could be therapeutically beneficial for the treatment of such dominantly inherited diseases5, 6, 7. We generated a lentiviral vector to mediate expression of RNAi molecules specifically targeting the human SOD1 gene (SOD1). Injection of this vector into various muscle groups of mice engineered to overexpress a mutated form of human SOD1 (SOD1 G93A) resulted in an efficient and specific reduction of SOD1 expression and improved survival of vulnerable motor neurons in the brainstem and spinal cord. Furthermore, SOD1 silencing mediated an improved motor performance in these animals, resulting in a considerable delay in the onset of ALS symptoms by more than 100% and an extension in survival by nearly 80% of their normal life span. These data are the first to show a substantial extension of survival in an animal model of a fatal, dominantly inherited neurodegenerative condition using RNAi and provide the highest therapeutic efficacy observed in this field to date.


 Top
Abstract
Previous | Next
Table of contents
Full textFull text
Download PDFDownload PDF
Send to a friendSend to a friend

naturejobs

Competing financial interests
Figures & Tables
Supplementary info
Export citation
natureproducts

Search buyers guide:

 
ADVERTISEMENT
 
Nature Medicine
ISSN: 1078-8956
EISSN: 1546-170X
Journal home | Advance online publication | Current issue | Archive | Press releases | Supplements | Focuses | For authors | Online submission | For referees | Free online issue | About the journal | Contact the journal | Subscribe | Advertising | work@npg | Reprints and permissions | About this site | For librarians
Nature Publishing Group, publisher of Nature, and other science journals and reference works©2005 Nature Publishing Group | Privacy policy